Table 2.
rTg4510 mice were treated with either haloperidol at a dose of 21 mg/kg/week or vehicle for 2 weeks
| Region | Vehicle, N = 9, age = 17 ± 0.4 weeks | Haloperidol, N = 11, age = 17 ± 0.3 weeks | Δ ptau/total | P value | Effect size (95% CI) |
|---|---|---|---|---|---|
| Cortex | |||||
| PHF-1/DA31 | 42.1 ± 3.14 | 33.6 ± 2.36 | −8.53 ± 3.86 | .040 | 0.994 (0.061–1.928) |
| RZ3/DA31 | 24.4 ± 1.6 | 16.9 ± 1.06 | −7.55 ± 1.86 | .0007 | 1.824 (0.777–2.87) |
| CP13/DA31 | 47.4 ± 3.45 | 28.9 ± 1.58 | −18.5 ± 3.56 | <.0001 | 2.33 (1.29–3.47) |
| Striatum | |||||
| PHF-1/DA31 | 32.1 ± 1.79 | 26.0 ± 1.58 | −6.13 ± 2.38 | .019 | 1.16 (0.207–2.11) |
| RZ3/DA31 | 14.4 ± 0.632 | 12.28 ± 1.46 | −2.12 ± 1.17 | .231 | NS |
| CP13/DA31 | 28.8 ± 2.37 | 22.1 ± 1.38 | −6.72 ± 2.63 | .0198 | 1.15 (0.199–2.10) |
| Hippocampus | |||||
| PHF-1/DA31 | 108.2 ± 7.53 | 93.9 ± 5.72 | −14.3 ± 9.3 | .141 | NS |
| RZ3/DA31 | 22.99 ± 2.61 | 18.4 ± 1.06 | −4.60 ± 2.62 | .0965 | NS |
| CP13/DA31 | 101.3 ± 6.078 | 104.1 ± 3.82 | +2.79 ± 6.92 | .692 | NS |
Abbreviation: NS, nonsignificant.
NOTE. Total tau (DA31) and phosphotau were quantified with ELISA. Phosphotau (ptau) was quantified using an ensemble of antibodies: PHF-1 (pSer396/404); CP13 (pSer202); and RZ3 (pThr231); and a ratio of ptau/DA31 was calculated for each antibody in each region. Changes (Δ ptau/total) in the ratio of ptau/DA31 (arbitrary units) represent the difference between mean ptau/DA31 of vehicle treated mice and mean ptau/DA31 of haloperidol treated mice.
NOTE. P < .05 was considered significant, and for each significant difference effect sizes were calculated with 95% confidence intervals.